MUC1 and lung carcinoma: BLP25 (Tecemotide®) (also known as L-BLP25 and Stimuvax) is a liposomal vaccine, which is formed from the immunoadjuvant monophosphoryl lipid A, and three lipid components (cholesterol, dimyristoyl phosphatidylglycerol, and dipalmitoyl phosphatidylcholine) (21) that harbors a 25 amino acid synthetic immunodominant core peptide of MUC1 TAA that has been shown to elicit a strong T-cell immune response both in transgenic murine lung cancer models and in patients (21–23).